Sarah L. Chamlin MD
Professor of Pediatrics and Dermatology, Northwestern University Feinberg School of Medicine; Attending Physician, the Ann and Robert H. Lurie Children’s Hospital of Chicago, specializing in Pediatric Dermatology, Chicago, IllinoisDr. Sarah Chamlin is Professor of Pediatrics and Dermatology at Northwestern University Feinberg School of Medicine and an attending physician at Lurie Children’s Hospital, specializing in pediatric dermatology.
Her clinical interests include hemangiomas (she is an active member of the Hemangioma Investigator Group) and other vascular lesions, hair and nails, and general pediatric dermatology. Her research interests include quality-of-life measurement in children and teens with skin disease and hemangiomas.
After receiving her medical degree from Rush Medical College in Chicago, Dr. Chamlin underwent residency training in pediatrics at Children’s Memorial Hospital in Chicago and in dermatology at the University of California, San Francisco. She completed her fellowship in pediatric dermatology at the University of California San Francisco Medical Center.
Disclosures
- Consultant: Regeneron; Sanofi
Recent Contributions to PracticeUpdate:
- Consensus Treatment Guidelines for the Use of Methotrexate in Patients With Inflammatory Skin Diseases
- Efficacy and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis
- Diagnosis and Management of Midline Cutaneous Anomalies of the Craniospinal Axis
- Topical Moisturizer Use Meaningfully Reduces Disease Severity in Atopic Patients With Xerosis
- Characterizing Clinical and Epidemiologic Data Regarding BASCULE Syndrome
- 2023 Top Story in Dermatology: Efficacy and Managing Long-Term Use of Dupilumab
- Risk and Characteristics of Melanoma and Melanocytic Nevi in Patients With Neurofibromatosis Type 1
- Atypical Cutaneous Findings of Hand–Foot–Mouth Disease in Children
- Prognostic Factors for Long-Term Aesthetic Outcomes in Patients With Infantile Haemangioma Treated With Beta Blockers
- Outcomes of Extending Dupilumab Dosing Intervals in Patients With Atopic Dermatitis